Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

331 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older who have been previously immunized with at least one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS). All subjects will receive 3 doses of 13vPnC, with each study vaccine dose given approximately 6 months apart.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

NCT00962780

HIV Infections Pneumococcal Infections

COMPLETED PHASE3

Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.

NCT00148824

HIV Infections

COMPLETED PHASE2

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

NCT03039491

HIV Lipodystrophy Aging

COMPLETED EARLY_PHASE1

Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects

NCT00706550

HIV Infections

COMPLETED NA

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

NCT03838497

Streptococcal Pneumonia HIV/AIDS

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Pneumococcal Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

13-valent pneumococcal conjugate vaccine

Intervention Type BIOLOGICAL

Three doses of 13vPnC given 6 months apart.

Blood draw

Intervention Type PROCEDURE

Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

13-valent pneumococcal conjugate vaccine

Three doses of 13vPnC given 6 months apart.

Intervention Type BIOLOGICAL

Blood draw

Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

13vPnC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects aged 18 years or older at the time of enrollment.
* All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control from the signing of the informed consent form (ICF) until 3 months after the last dose of investigational product.
* Documented vaccination with 1 or more doses of 23vPS at least 6 months before study enrollment.
* CD4+ T-cell count \>= 200 cells/µ, obtained on the most recent 2 occasions within 6 months before the first investigational product vaccination.
* HIV-infected subjects with viral load \<50,000 copies/mL, obtained on the most recent 2 occasions within 6 months before the first investigational product vaccination.
* Subject is receiving a stable dose of HAART for at least 6 weeks prior to the first investigational product vaccination, or not currently receiving antiretroviral therapy.
* Subject is expected to be available for the entire study period (approximately 18 months) and can be contacted by telephone.
* Subject must be able to complete an electronic diary (e-diary) and complete all relevant study procedures during study participation.
* Subject is deemed to be eligible for the study on the basis of medical history, physical examination, and clinical judgment. (Note: Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 6 weeks before investigational product vaccination, are eligible.)

Exclusion Criteria

* Subjects with active AIDS related illness, including opportunistic infections or malignancy.
* Evidence of current illicit substance and/or alcohol abuse, that in the investigator's opinion, precludes the subject from participating in the study or interferes with the evaluation of the study objectives..
* Receipt of any licensed or experimental pneumococcal conjugate vaccine prior to enrollment.
* Contraindication to vaccination with pneumococcal conjugate vaccine.
* Previous anaphylactic reaction to any vaccine or vaccine-related component.
* History of culture-proven invasive disease caused by Streptococcus pneumoniae within the last year.
* Current anticoagulant therapy or a history of bleeding diathesis or any condition associated with prolonged bleeding time that would contraindicate intramuscular injection. (Note: Use of antiplatelet drugs, such as aspirin and clopidogrel, is permitted.)
* Pregnant or breastfeeding women, as defined by history or positive human chorionic gonadotropin (hCG) urine test. All women of childbearing potential must have a urine pregnancy test.
* History of active hepatitis with elevation in pretreatment aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values \>5 times the upper limit of normal within the last 6 months.
* Serious chronic disorder or any other disorder that, in the investigator's opinion, precludes the subject from participating in the study or interferes with the evaluation of the study objectives. (Note: Serious chronic disorders include metastatic malignancy, severe chronic obstructive pulmonary disease requiring supplemental oxygen, end-stage renal disease with or without dialysis, and clinically unstable cardiac disease).
* Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of, the study, or could preclude the evaluation of the subject's response.
* History of splenectomy.
* Receipt of any blood products, including immunoglobulin, within 42 days before investigational product vaccination until the last blood draw for the study (approximately 13 months after the first investigational product vaccination).
* Evidence of dementia or other severe cognitive impairment.
* Subject who is, in the opinion of the investigator, unable to receive a vaccination in the deltoid muscle of either arm because of insufficient muscle mass.
* Participation in another study using investigational product from 28 days before study enrollment until the blood draw at visit 6. Between the blood draw at visit 6 and the 6 month follow-up telephone call (visit 7), use of investigational product must be discussed with the Medical Monitor. (Note: Participation in purely observational studies is acceptable.)
* Residence in a nursing home, long-term care facility, or other institution or requirement of semi-skilled nursing care. An ambulatory resident of a retirement home or village is eligible for the trial.
* Subject who is a direct relative (child, grandchild, parent, or grandparent) of study personnel, or who is study personnel.

Temporary Delay Criteria:

* Current febrile illness (oral temperature of =38.0°C \[100.4°F\]) or other acute illness within 48 hours before study vaccine administration.
* Currently receiving antibiotic therapy, or has completed a course of antibiotic therapy within 10 days before study vaccine administration.
* Receipt of novel influenza A (H1N1) vaccine within 14 days before investigational product vaccination (seasonal influenza vaccine can be given at any time at the discretion of the investigator).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No